The EU says French company Servier paid Teva and others to delay generic Perindropil.
The EU antitrust regulator has fined Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) €15.6 million ($21.3 million) for delaying the launch of a generic version of high blood pressure treatment Perindropil. Altogether five drug companies were fined €427.7 million ($582.2 million) on the subject as part of the "pay for delay" policy of the European and US regulatory authorities.
The EU charges that the French company Servier systematically bought out competitive threats through payments to Teva and the other companies not to launch generic Perindropil.
Teva denies any wrongdoing. “We stand by our belief that Teva did not engage into any anti-competitive behavior.”
Published by Globes [online], Israel business news - www.globes-online.com - on July 10, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014